Latest Articles

Publication Date
Eli Lilly Builds $1.5 Billion Stockpile of Oral GLP-1 Drug as Study Shows 66% Drop in Endometrial Cancer Risk for Certain Patients - geneonline.com

Eli Lilly Builds $1.5 Billion Stockpile of Oral GLP-1 Drug as Study Shows 66% Drop in Endometrial Cancer Risk for Certain Patients geneonline.com

Published: Feb. 16, 2026, 10:55 a.m.
Atypical gelation of Elagolix sodium in aqueous media: Mechanistic insights and Inhibition via coamorphization.

Elagolix sodium (ELS), a non-peptide oral gonadotropin-releasing hormone receptor (GnRH) antagonist approved for the treatment of endometriosis-associated pain, displays atypical gelation in aqueous environments along with challenging physical properties such …

Published: Feb. 12, 2026, midnight
Shorter Anogenital Distance in Women with Adenomyosis Diagnosed by MUSA 2022 Criteria: A Prospective Case-Control Study.

Objective: The objective was to investigate the association between anogenital distance (AGD) and adenomyosis in reproductive-age women and to evaluate the potential of AGD as a non-invasive biomarker reflecting prenatal …

Published: Feb. 7, 2026, midnight
Efficacy and Safety of Traditional Chinese Medicine Retention Enema for Endometriosis: A Systematic Review and Meta-Analysis.

Background/Objectives: Herbal retention enema is widely used in Traditional Chinese Medicine for the management of endometriosis; however, its clinical efficacy and safety have not been systematically evaluated. Methods: Ten electronic …

Published: Feb. 6, 2026, midnight
Safety, Pharmacokinetics, and Sex Hormone Suppression of LY01021 versus Relugolix: A Single- and Multiple-Dose Escalation Study.

LY01021 is a novel oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of various sex hormone-dependent disorders. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), …

Published: Feb. 5, 2026, midnight
The role of Fusobacterium nucleatum in the pathogenesis of endometriosis: A microbial and microenvironmental perspective.

Endometriosis is a chronic, inflammatory gynecological condition characterized by the ectopic growth of endometrial-like tissue, with an unclear etiology and limited treatment efficacy. Recent studies implicate the oral and gut …

Published: Feb. 4, 2026, midnight
Oral Microcapsules Encapsulating Endometrial Regenerative Cell-Derived | IJN - Dove Medical Press

Oral Microcapsules Encapsulating Endometrial Regenerative Cell-Derived | IJN Dove Medical Press

Published: Feb. 2, 2026, 7:47 a.m.
Safety and efficacy of hormonal therapies used to treat endometriosis in women suffering migraine.

Hormonal therapy is the cornerstone of long-term endometriosis management, especially for women deferring surgery. In patients with comorbid migraine - a common, disabling condition - therapeutic choices must balance efficacy …

Published: Feb. 2, 2026, midnight
Oral diclofenac potassium and intramuscular hyoscine-n-butyl bromide versus oral diclofenac potassium alone for pain relief during hysterosalpingography: a double blind randomized controlled trial.

Hysterosalpingography (HSG) is an important diagnostic tool in infertility, often associated with pain and tubal spasms, potentially resulting in false proximal tubal occlusions. This randomised controlled trial compared oral diclofenac …

Published: Jan. 29, 2026, midnight
Myrrh ameliorates endometriosis by enhancing ER stress-related apoptotic cell death.

Endometriosis is characterized by ectopic growth of endometrial tissue causing severe abdominal pain and inflammation during disease progression. Myrrh, a resin collected from trees of genus Commiphora known for its …

Published: Jan. 29, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!